Introduction to Tesamorelin 12 mg with Ipamorelin 4 mg
Tesamorelin and Ipamorelin are synthetic peptides frequently studied in laboratory settings for their complementary roles in growth hormone (GH) regulation. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective growth hormone secretagogue (GHS) that interacts with the ghrelin receptor. This combination is provided as lyophilized powders (Tesamorelin 12 mg and Ipamorelin 4 mg), and is commonly used in non-clinical research models to explore GH pulse dynamics, IGF-1 modulation, and related signaling cascades.
Research Applications
In preclinical research and in vitro studies, Tesamorelin and Ipamorelin have been investigated for their distinct and synergistic effects on:
Pituitary GH-releasing pathways via GHRH and GHS receptors
Pulsatile GH secretion and feedback regulation
IGF-1 axis modulation in hepatic and extrahepatic models
Endocrine signaling mechanisms associated with peptide-mediated growth responses
| Property | Description |
|---|---|
| Chemical Sequence | Tesamorelin: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 (44 amino acids) Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 amino acids) |
| CAS | Tesamorelin: 901758-09-6 Ipamorelin: 170851-70-4 |
| Molecular Formula | Tesamorelin: C211H366N72O67S Ipamorelin: C38H49N9O5 |
| Molecular Weight | Tesamorelin: 5135.78 g/mol Ipamorelin: 711.85 g/mol |
| CID | Tesamorelin: 44147474 Ipamorelin: 9831659 |
| Appearance | White Lyophilized Powder (reconstituted for injection) |
| Purity | ≥98% for each peptide (verified by HPLC, per USP <621>) |
| Storage | Store at -20°C (lyophilized) or 2–8°C (reconstituted); stable for 24 months (lyophilized), 30 days (reconstituted) |
| Testing Standards | Complies with GMP (21 CFR Part 211), ISO/IEC 17025-accredited lab analysis |
Learn More About Tesamorelin 12 mg with Ipamorelin 4 mg
- “Tesamorelin reduces visceral fat by 15% in HIV lipodystrophy” (Falutz et al., NEJM, 2010).
- “Ipamorelin enhances GH release with minimal side effects” (Peptides, 1998).
- “Synergistic effects of GHRH and GHS in GH optimization” (Journal of Endocrinology, 2015).
- “Tesamorelin improves insulin sensitivity and lipid profiles” (Diabetes Care, 2011).
- “Peptide combinations for metabolic health and body composition” (Frontiers in Endocrinology, 2020).
Research Use Only
This product is supplied strictly for research and laboratory use only. It is not approved for human or animal use, and must not be misbranded or marketed as a drug, dietary supplement, or therapeutic product. All usage must comply with applicable local, state, and federal laws. The end-user assumes full responsibility for proper handling and application.
